Jonathan Garen

Jon joined Nocion as Chief Business Officer in September of 2021. He has over 20 years of experience in Strategy, Business Development, M&A, and Commercial Planning in companies ranging from large and medium pharma to startup biotech. He has completed over 25 licensing, acquisition, and renegotiations leading to multiple approved products.

Mr. Garen joins Nocion from uniQure, where he served as Chief Business Officer with responsibility for corporate development, commercialization, strategic planning and alliance management. At uniQure, he led the commercial planning for the first in class hemophilia b gene therapy and strategic planning for pipeline development, and completed several transactions to grow the pipeline and partner uniQure’s hemophilia b program with a global pharmaceutical company. Mr. Garen was also a member of the Board of the Alliance for Regenerative Medicine, an international organization focused on the issues facing regenerative medicine and advanced therapies including gene therapy.

Prior to joining uniQure, Mr. Garen was Chief Business Officer at Syros Pharmaceuticals, where he was responsible for business transactions. Before Syros, Mr. Garen was the Assistant Vice President of Business Development at Forest Laboratories where he worked from 2003 to 2015. At Forest Laboratories, Mr. Garen was responsible for numerous acquisitions and license agreements to build the companies’ pipeline in all its focus therapeutic areas, and led a team of business development professionals. Earlier in his career, Mr. Garen was Director of Global Licensing with Pharmacia Corporation and a Founder and Vice President of Technology Exchange, Inc.

Mr. Garen holds a Master of Environmental Studies degree from Yale University and a Bachelor of Science degree in Physics from the Massachusetts Institute of Technology.